Navigation Links
Slo-Niacin® Dietary Supplement Shown to Support 'Good' Cholesterol (HDL)

MAPLE GROVE, Minn., Nov. 17, 2010 /PRNewswire/ -- People who are searching for a niacin dietary supplement to support heart health with less potential for flushing can turn to Slo-Niacin®.  Trusted by healthcare professionals for more than 20 years, Slo-Niacin® is a niacin supplement that has been shown in clinical studies to boost "good" cholesterol (HDL).

"Slo-Niacin® features a unique patented polygel® system that gradually delivers niacin to the body," said Dr. Carl Lavie, medical director of Cardiac Rehabilitation and Prevention, John Ochsner Heart and Vascular Institute, New Orleans, LA.  "I recommend Slo-Niacin® to my patients because its innovative formulation sets it apart from other dietary supplement niacin products. Over-the-counter niacin products may vary considerably in effect and safety profiles, and Slo-Niacin® has demonstrated quality in medical studies for nearly 20 years."

Slo-Niacin® Tablets utilize a patented polygel® controlled-release delivery system not available in other dietary supplement niacin products.  This technology ensures the gradual and measured release of niacin in the body and is designed to reduce the incidence of flushing commonly associated with immediate-release niacin use.

"It is important to recognize that Slo-Niacin® is a controlled-release niacin and not an immediate-release or 'flush-free' niacin," added Dr. Lavie.  "Immediate-release niacin requires niacin to be taken several times a day, and flushing can be a problem that significantly limits patient tolerability.  'Flush-free' niacins may not cause flushing, but they have not been shown to have any significant effect in cholesterol management."

Niacin is a type of B vitamin that occurs naturally and aids in the function of the digestive system, skin and nerves.  Niacin is sometimes referred to as nicotinic acid and has been used to help manage cholesterol since the 1950s.  When used under the care and monitoring of a healthcare provider, niacin is the most effective agent available for increasing HDL.  Niacin (nicotinic acid) is effective alone or as a complement to statins.

About Slo-Niacin® TabletsSlo-Niacin® is economical and often costs less than an insurance co-payment, at approximately $16 per month for one hundred 500 mg tablets. Three dosage strengths of Slo-Niacin® Tablets are available to help meet a person's individual goals (250 mg, 500 mg, and 750 mg).  However, taking more than 500 mg of niacin daily should be done only under the advice and monitoring of your healthcare professional.  Slo-Niacin® Tablets are manufactured by Upsher-Smith Laboratories, Inc., a trusted manufacturer of high quality prescription and dietary supplement products, and are conveniently available at pharmacies and other retailers nationwide.  In the 20 years that Upsher-Smith has been manufacturing Slo-Niacin®, more than 10 million bottles have been sold. For more information, visit for coupons and a store locator.

About Upsher-Smith Laboratories, Inc. Upsher-Smith Laboratories, Inc. is a rapidly growing pharmaceutical company that manufactures and markets both prescription and consumer products. Privately held since 1919, the company strives to recognize the unmet healthcare needs of our customers. Upsher-Smith prides itself in providing safe, effective, and economical therapies to the ever-challenged healthcare environment. For additional information about Upsher-Smith, visit

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.Important Safety InformationRead the information leaflet provided with each bottle of Slo-Niacin® Tablets. Do not use Slo-Niacin® Tablets if you have a known sensitivity or allergy to niacin.  Do not take niacin unless under your healthcare provider's supervision if you have heart disease (particularly, recurrent chest pain or recent heart attack), gallbladder disease, gout, arterial bleeding, glaucoma, diabetes, impaired liver function, stomach ulcers, or are pregnant or lactating.  Before taking more than 500 mg/day, call your healthcare provider.  If you are taking high blood pressure or cholesterol-lowering drugs, call your healthcare provider before taking niacin due to possible interactions. Case reports of unexplained muscle-related complaints, including discomfort, weakness, or tenderness, have been documented with HMG-CoA Reductase Inhibitors (statins) in combination with niacin. Increased uric acid, glucose, and abnormal liver function tests have been reported in persons taking 500 mg/day or more.  Discontinue use and call your healthcare provider immediately if you experience persistent flu-like symptoms (nausea, vomiting, not feeling well), loss of appetite, decreased and dark-colored urine, muscle discomfort or weakness, irregular heartbeat or vision problems.  Niacin may cause temporary flushing, itching and tingling, feelings of warmth and headache, particularly when beginning, increasing dosage or changing brands.  This safety information is not all-inclusive. For more information, contact your healthcare provider, call 1-800-654-2299, or visit Clinic.  Accessed October 22, 2010. MedlinePlus. Niacin. Accessed October 21, 2010. American Heart Association. Accessed October 22, 2010. Harvard Health Letter. "Niacin into the void: Failure of HDL cholesterol drug may be this B vitamin's big chance." April 2007. Lavie CJ, Mailander L, Milani. "Marked benefit with sustained-release niacin therapy in patients with 'isolated' very low levels of high-density lipoprotein cholesterol and coronary artery disease." Am J Cardiol. 1992;69:1083-1085. Squires RW, Allison TG, Gau GT, et al. "Low-Dose, Time-Release Nicotinic Acid: Effects in Selected Patients With Low Concentrations of High-Density Lipoprotein Cholesterol." Mayo Clin Proc. 67:855-860, 1992. Gray DR, Morgan T, Chretien SD, Kashyap ML. "Efficacy and Safety of Controlled-Release Niacin in Dyslipoproteinemic Veterans." Ann  Intern Med. 1994;121:252-258. Knopp RF, Retzlaff BM, Fish B et al. "The SLIM study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia." Journal of Clinical Lipidology, Volume 3, Issue 3, Pages 167-178. May 2009.Slo-Niacin product information. Upsher-Smith Laboratories, 2010. Accessed October 22, 2010. website. Accessed October 22, 2010.104546.02


SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VSL#3® Probiotic Shown Effective in Dietary Management of Children With Irritable Bowel Syndrome
2. SCOLR Pharma, Inc. Licenses Dietary Supplements
3. Muscadine Grape Skin Dietary Supplement Protects against Cancer Therapy Radiation Side Effects
4. Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone
5. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
6. New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women
7. Seeking Safety in Supplements
8. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
9. Supplemental Oxygen Company Offers Steps to Improve COPD Patients Lives
10. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
11. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Thanks to a donor with ... Mary,s Medical Center,s Sister Diane Grassilli Center for Women,s ... in San Francisco . ... stepped forward with a gift of $617,320 that allowed ... Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA ... EPIX ) announced today that the first patient ... of EPI-506 as a treatment for metastatic castration-resistant prostate ... and Canada.  --> the ... In the Phase 1/2 clinical trial, ESSA intends ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent ... bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to ... the patent-pending RECOVERY BRA for added comfort and support. The bra is easier ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted to ... raising public awareness of the disorder while helping to bring expert medical care ... to bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert ...
(Date:11/24/2015)... Florida (PRWEB) , ... November 25, 2015 , ... ... planning and monitoring. Their Care Plan software creates an agreement between the ... patient care plan, including financial, scheduling, monitoring, notification, and projections. Click ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a ... Dr. Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in ... and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the ...
(Date:11/24/2015)... ... November 25, 2015 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... upcoming Clinical Trial Supply East Asia Conference, to be held at the InterContinental ...
Breaking Medicine News(10 mins):